<h4>Background</h4>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard of care for hormone receptor (HR)-positive, HER2-negative advanced/metastatic breast cancer (BC). This evidence concerns the gene NR4A1 and breast cancer.